Indium In 111-DOTA-Daratumumab

BIOLOGICAL2 trials

Sponsors

City of Hope Medical Center

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Phase 1

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

RecruitingNCT05363111

City of Hope Medical CenterRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2022-11-22End: 2027-03-23Target: 15Updated: 2025-10-29

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

RecruitingNCT06287944

City of Hope Medical CenterAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2025-07-01End: 2028-05-19Target: 15Updated: 2026-07-31

Related Papers

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Blood2025-11-03